Joint Pain News and Research

RSS

FDA approves Lysteda for treating menorrhagia

Xanodyne Pharmaceuticals, Inc., an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management, announced today that Lysteda(TM) (tranexamic acid) oral tablets has received U.S. Food and Drug Administration (FDA) approval for treatment of women suffering from cyclic heavy menstrual bleeding (HMB), also known as menorrhagia.

16 Nov 2009

Nutra Pharma to market its OTC pain reliever in Brazil and Colombia, begins the drug registration process

Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it plans to begin the drug registration process in Brazil and Colombia for its over-the-counter (OTC) pain reliever. The company is currently marketing a similar drug in the United States under the brand name Cobroxin for the treatment of moderate to severe (Stage 2) chronic pain.

13 Nov 2009

Tart cherry juice may help runners recover quickly and effectively from post-race pain

From gold medalists to weekend warriors, athletes at every level are in search of new ways to reduce pain and enhance post-exercise recovery. Recent research shows that drinking tart cherry juice may help runners recover more quickly and effectively from post-race pain.

26 Oct 2009

Physical therapists can promote early diagnosis of breast cancer-related lymphedema

As breast cancer awareness month is observed during October, the American Physical Therapy Association (APTA) is hoping to shine a spotlight on lymphedema, a chronic, debilitating and often irreversible side effect of cancer treatment.

19 Oct 2009

Initiative calls for more research and improved treatment methods on musculoskeletal pain

The Global Year Against Musculoskeletal Pain launches today, focusing attention on one of the largest and most significant areas of pain.

19 Oct 2009

Cobroxin OTC pain reliever is now available online

Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that its over-the-counter pain reliever, Cobroxin, is available for sale online at Cobroxin.com.

15 Oct 2009

Strengthen key muscles in the foot to improve overall performance

With summer weather finally gone, more Canadians will spend hours at the gym sculpting their muscles, but most will neglect one of the most important ones - the foot. Recent studies show neglecting the feet leads to chronic foot, knee, back, and joint pain. By strengthening key muscles in the foot, a person can improve their overall performance, energy and pain.

13 Oct 2009

Legendary coach helps raise awareness on osteoarthritis

After leading the U.S. men’s basketball team to Olympic gold last year and two weeks before the start of his 30th season as head coach of Duke University’s men’s basketball team, Mike Krzyzewski (Coach K), 61, is teaming up with the Arthritis Foundation to help raise awareness of the disease that nearly ended his coaching career 10 years ago.

13 Oct 2009

Muscle Flex develops a strong portfolio of 'Water' related products to maintain healthy lifestyle

Muscle Flex Inc. (www.MuscleFlexInc.com) announced today that it is developing a strong portfolio of "Water" related products to market using its direct response, online ecommerce and traditional retail methods. Muscle Flex® regards "Water" as potentially the most important ingredient in maintaining a healthy lifestyle and it is estimated that as much as 75% of Americans do not drink enough good clean water.

8 Oct 2009

Nutra Pharma manufactures first commercial batch of Cobroxin

Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it has completed manufacturing the first commercial batch of Cobroxin and has successfully released it for final distribution.

3 Oct 2009

Plexxikon commences patient dosage in PLX4032 trials for metastatic melanoma

Plexxikon Inc. announces that enrollment has been initiated and the first patient has been treated in the first of two pivotal trials of PLX4032 (RG7204) in patients with metastatic melanoma. PLX4032 is a novel, oral and highly selective drug that targets the BRAFV600E cancer-causing mutation occurring in about 50 percent of melanomas and about eight percent of all solid tumors.

30 Sep 2009

Estrogen withdrawal may play a significant role in joint pain during breast cancer treatment

Aromatase inhibitors, the same drugs that have buoyed long-term survival rates among breast cancer patients, also carry side effects including joint pain so severe that many patients discontinue these lifesaving medicines. New University of Pennsylvania School of Medicine research, however, has uncovered patterns that may help clinicians identify and help women at risk of these symptoms sooner in order to increase their chances of sticking with their treatment regimen.

29 Sep 2009

Phase 1 extension study results of Plexxikon's PLX4032 in metastatic melanoma patients encouraging

Plexxikon Inc. today announced encouraging clinical data from a Phase 1 extension study of PLX4032 (RG7204) in metastatic melanoma patients, which expand the results announced from the initial phase of the study. PLX4032 is a novel, oral and highly selective drug that targets the BRAFV600E cancer-causing mutation that occurs in about 50 percent of melanomas and about eight percent of all solid tumors.

23 Sep 2009

Drug registration process for Nutra Pharma's pain reliever begins

Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it plans to begin the drug registration process in Canada and Europe for its over-the-counter (OTC) pain reliever. The company is currently marketing a similar drug in the United States under the brand name Cobroxin for the treatment of moderate to severe (Stage 2) chronic pain.

22 Sep 2009

Postmenopausal women benefit as much from exercise as younger women

In two papers based on the experiments and published in recent months, UC Berkeley researchers report that postmenopausal women can achieve the same health benefits from regular, vigorous exercise as younger women do.

21 Sep 2009

Campaign to educate customers on chronic pain management

VitalWear, Inc. (www.vitalwear.com), a leader in thermal compression medical devices announced that it is launching a Direct Mail and Web campaign in an effort to educate customers on a recent report from the Center for Disease Control (CDC), stating that among all diabetics, 52% suffer from arthritis.

11 Sep 2009

Nutra Pharma’s Cobroxin pain reliever is "Best New Product" at the ECRM Conference

Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that its recently launched pain reliever, Cobroxin, was selected as the “Best New Product” at the Efficient Collaborative Retail Marketing (ECRM) Conference. Cobroxin was chosen as the award recipient by conference attendees, including several of the leading national retailers.

31 Aug 2009

XenaCare Holdings to market Cobroxin pain reliever drug in U.S.

Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it has successfully completed a licensing agreement that grants XenaCare Holdings (OTCBB:XCHO) ongoing exclusive United States marketing and distribution rights for Cobroxin in return for meeting specific minimum performance requirements.

27 Aug 2009

Link between collagen deficiency and osteoarthritis found in mice

Osteoarthritis (OA) and degenerative disc disease (DDD) are common, chronic musculoskeletal disorders. Both diseases cause joint pain, loss of function, and decreased quality of life for the more than 27 million OA and 59 million DDD suffers in the US. According to a 2003 Medical Expenditure Panel Survey, arthritis such as OA costs the U.S. economy nearly $128 billion per year in medical care and indirect expenses including lost wages and productivity.

27 Aug 2009

Collagen deficiency in mice causes premature development of osteoarthritis and degenerative disc disease

27 Aug 2009

Joint Pain News and Research

FDA approves Lysteda for treating menorrhagia

Nutra Pharma to market its OTC pain reliever in Brazil and Colombia, begins the drug registration process

Tart cherry juice may help runners recover quickly and effectively from post-race pain

Physical therapists can promote early diagnosis of breast cancer-related lymphedema

Initiative calls for more research and improved treatment methods on musculoskeletal pain

Cobroxin OTC pain reliever is now available online

Strengthen key muscles in the foot to improve overall performance

Legendary coach helps raise awareness on osteoarthritis

Muscle Flex develops a strong portfolio of 'Water' related products to maintain healthy lifestyle

Nutra Pharma manufactures first commercial batch of Cobroxin

Plexxikon commences patient dosage in PLX4032 trials for metastatic melanoma

Estrogen withdrawal may play a significant role in joint pain during breast cancer treatment

Phase 1 extension study results of Plexxikon's PLX4032 in metastatic melanoma patients encouraging

Drug registration process for Nutra Pharma's pain reliever begins

Postmenopausal women benefit as much from exercise as younger women

Campaign to educate customers on chronic pain management

Nutra Pharma’s Cobroxin pain reliever is "Best New Product" at the ECRM Conference

XenaCare Holdings to market Cobroxin pain reliever drug in U.S.

Link between collagen deficiency and osteoarthritis found in mice

Collagen deficiency in mice causes premature development of osteoarthritis and degenerative disc disease

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News